RA- tsDMARDs DI Flashcards
tsDMARDs/JAKis drugs
Tofacitinib (Xeljanz)
Baricitinib (Olumiant)
Upadacitinib (Rinvoq)
JAKis MoA
Inhibit JAK enzymes to block transcription of inflammatory genes
Xeljanz dosing
IR: 5mg PO BID
XR: 11mg PO QD
Olumiant dosing
2mg PO QD
Rinvoq dosing
15mg PO QD
Xeljanz ADEs
Increased HDL and LDL
HA
UTI
URTI
GI perforation
Anemia
Neutropenia
Skin cancer
PE
Infections
Olumiant ADEs
Increased AST/ALT
Nausea
Herpes zoster and other infections
GI perforation
Thrombosis
Infections
Rinvoq ADEs
Increased HDL, LDL, TC, and AST/ALT
Nausea
URTI
Skin cancer
GI perforation
Thrombosis
Anemia
Neutropenia
Infections
JAKis BBW
Risk of opportunistic infections, lymphomas, other malignancies, thrombosis (DVT, PE, arterial thrombosis)
What should you screen for before starting a JAKi?
Latent TB and Hep B infections
When to use JAKis based on the guidelines
Moderate-high disease activity despite DMARD monotherapy
Unable to tolerate/CI to csDMARD
What to use JAKis with
Can be used alone or in combination with MTX or other NONBIOLOGIC DMARDs